Skip Navigation

International Journal of Epidemiology 2006 35(5):1312-1313; doi:10.1093/ije/dyl137
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Edwards, C.
Right arrow Articles by Arden, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, C.
Right arrow Articles by Arden, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2006; all rights reserved.

Commentary

Commentary: Statins and fracture—why the confusion?

CJ Edwards1,2,* and NK Arden1,2

1 MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK
2 Department of Rheumatology, Southampton General Hospital, Southampton, UK

* Corresponding author. Department of Rheumatology, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK. E-mail: cedwards@soton.ac.uk.

The first 10% of the full text of this article appears below.

In 1999 a paper published in Science suggested that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) increased bone formation in rodents by effects on a potent bone forming cytokine bone morphogenetic protein-2 (BMP-2).1 Subsequent studies have suggested that statins increase bone mineral density (BMD) in humans2 and have investigated whether statin use is associated with reduced fracture risk. The fracture risk studies include four case–control studies, five cohort studies in which fracture end points where documented, and the post hoc analysis of the effect of statins on fracture in two cardiovascular outcome studies. To date there are no prospective . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?